Thus, mitotic-based therapies are currently been refined, and small molecule inhibitors against several centrosome and mitotic regulators are currently in clinical trials, including a phase II trial with the inhibitor ENMD-2076, which is specific against the Aurora kinase A and angiogenesis kinases, against metastatic, triple-negative breast cancers [68]. This evidence concerns the gene AURKA and triple-negative breast carcinoma.